Swedish Orphan Biovitrum
Tracked across 2 events · 12 articles · First seen Apr 09, 2026 · Last active Jun 26, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Swedish Orphan Biovitrum received a Complete Response Letter from the FDA for its Biologics License Application for National Association of Securities Professionals, requiring additional data and addressing facility deficiencies. This delays the approval process for their drug.
Jun 26, 2026 · 6 articles
Tech
Impact: Swedish Orphan Biovitrum is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
100
United States — Food and Drug Administration issued Complete Response Letter Swedish Orphan BiovitrumFDA issues CRL for Sobi's NASP
80
Swedish Orphan Biovitrum will request meeting United States — Food and Drug AdministrationFDA issues CRL for Sobi's NASP
ERGEN INTELLIGENCE
Track Swedish Orphan Biovitrum live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard